SequelSEC

Starling Oncology, Inc. STLN

Services-Offices & Clinics of Doctors of Medicine · CIK 0001799191 · Fiscal year ends 1231

Revenue
$587.24M
Fiscal year ended 2026-06-30
Operating income
-$26.09M
Fiscal year ended 2026-06-30
Free cash flow
-$3.29M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$137.20MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.39Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Services-Offices & Clinics of Doctors of Medicine filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
FCF margin-5.5%0th
SBC / revenue0.9%14th
CapEx / revenue0.6%25th
Net margin-12.1%29th
Revenue YoY growth27.8%71th
Current ratio1.59x57th
Operating margin-7.2%43th

Starling Oncology, Inc. (STLN) reported revenue of $587.24M and net income of -$36.29M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Starling Oncology, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Offices & Clinics of Doctors of Medicine.

Income

Starling Oncology, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$587.24M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$26.09M
Net income-$36.29M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$36.29M
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrative$111.45M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Starling Oncology, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalentsUnavailable
Total assets$178.23M
Current assets$128.99M
Total liabilities$203.15M
Current liabilities$94.94M
Total equity incl. NCI-$24.91M
Temporary (mezzanine) equityUnavailable
Inventory$20.01M
Accounts receivable$66.35M
Goodwill$7.23M
Long-term debt$79.87M
Accounts payable$60.28M

Cash flow

Starling Oncology, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$328.00K
Capital expenditures$3.61M
Investing cash flow-$3.61M
Financing cash flow$14.09M
Net change in cashUnavailable
Stock-based compensation$5.10M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$6.81M

Derived

Starling Oncology, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$3.29M
Gross marginUnavailable
Operating margin-4.4%
FCF margin-0.6%
SBC / revenue0.9%
Current ratio1.36x
Revenue YoY growth38.4%
Net margin-6.2%
R&D / revenueUnavailable
CapEx / revenue0.6%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open STLN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.